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Background: Honey is a natural substance produced by honeybees and has nutritional and therapeutic uses. In
Ethiopia, honeys are used traditionally to treat wounds, respiratory infections and diarrhoea. Recent increase of drug
resistant bacteria against the existing antibiotics forced investigators to search for alternative natural remedies and
evaluate their potential use on scientific bases. Thus, the aim of this study was to evaluate the antibacterial effects
of different types of honeys in Ethiopia which are used traditionally to treat different types of respiratory and
gastrointestinal infections.
Methods: Mueller Hinton agar (70191) diffusion and nutrient broth culture medium assays were performed to
determine susceptibility of Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922) and resistant clinical
isolates (Methicillin resistant Staphylococcus aureus(MRSA), Escherichia coli(R) and Klebsiella pneumoniae (R), using
honeys of Apis mellifera and stingless bees in northern and north western Ethiopia.
Results: Honey of the stingless bees produced the highest mean inhibition (22.27 ± 3.79 mm) compared to
white honey (21.0 ± 2.7 mm) and yellow honey (18.0 ± 2.3 mm) at 50% (v/v) concentration on all the standard
and resistant strains. Stingless bees honey was found to have Minimum Inhibitory Concentration (MIC) of 6.25%
(6.25 mg/ml) for 80% of the test organisms compared to 40% for white and yellow Apis mellifera honeys. All the
honeys were found to have minimum bactericidal concentration (MBC) of 12.5% (12.5 mg/ml) against all the test
organisms. Staphylococcus aureus (ATCC 25923) was susceptible to amoxicillin, methicillin, kanamycine, tetracycline,
and vancomycine standard antibiotic discs used for susceptibility tests. Similarly, Escherichia coli (ATCC 25922) was
found susceptible for kanamycine, tetracycline and vancomycine. Escherichia coli (ATCC 25922) has not been tested
for amoxicillin ampicillin and methicillin. The susceptibility tests performed against Staphylococcus aureus (MRSA),
Escherichia coli (R) and Klebsiella pneumoniae (R) using three of methicillin, erythromycin, ampicillin, Penicillin and
amoxicillin discs were resistant. But, these drug resistant strains were susceptible to antibacterial agents found in
the honeys and inhibited from 16 mm to 20.33 mm.
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Conclusions: Honeys in Ethiopia can be used as therapeutic agents for drug resistant bacteria after pharmaceutical
standardization and clinical trials.
Keywords: Anticbacterial effects, Ethiopian honeys, Escherichia coli (ATCC 25922), Escherichia coli (R), Klebsiella
pneumoniae (R), Staphylococcus aureus (ATCC 25923), Staphylococcus aureus (MRSA)Background
Honey is a natural substance produced and stored in the
honeycombs by honeybees with carbohydrates constituting
about 95 to 97% of the dry weight of honey [1,2]. Fructose
and glucose are the most predominant sugars present
and responsible for most of the physical and nutritional
characteristics of honey [3,4]. The volatile compound
found in honey includes alcohols, ketones, aldehydes,
acids, esters and terpenes [5]. Phenolic acids (benzoic and
cinnamic acids) and flavonoids (flavanones, flavanols)
contribute significantly to the therapeutic capacity of
honey which varies greatly depending on the floral
source [6]. Different studies have shown honey to have
antimicrobial effect [7-11], anti-inflammatory effects [12],
anti-oxidant effects [13] and boosting of the immune
system [14]. Common Apinae honey bees honey (Apis
mellifera honey) and stingless honeybees honey are the
two types of honeys found in the world [15]. The common
honey bees (sub family Apinae) and stingless bees (sub
family Meliponinae) are grouped in the family Apidae
[16]. In Ethiopia, Apinae honeybees (Apis mellifera) are
mostly domestic unlike the wild stingless honeybees
which keep their honey in storage pots build of resinous
cerumen in the ground (“Tazma” honey) or in the tree
trunk (“Tinign” honey). Tazma and Tinign honeys are the
same as stingless bees could nest in the ground or tree
trunks depending their preferences. The different species
of stingless bees and their behaviour were not studied
in Ethiopia, although Apis mellifera and stingless bees
honeys have been tested for antimicrobial activities
against different bacteria [7,9-11] in addition to traditional
use of these honeys to treat wounds, respiratory infections
and diarrhoea. At present, Medihoney TM (a blend of
manuka and jelly bush honey) has been one of the first
medically certified honeys licensed as medical product
for professional wound care in Europe, America and
Australia [17]. Honey has shown considerable antibacterial
activity against a wide range of wound pathogens [18] as
well as against biofilms created by bacteria on wounds [19].
The antimicrobial (antibacterial, antiviral, antifungal and
antiparasitic) activities of honeys were reported due to
high osmolarity, acidity, hydrogen peroxide and phyto-
chemicals [17,18,20-25]. The major antibacterial effect,
however, was reported due to hydrogen peroxide [15,26-29].
Hydrogen peroxide is produced by the oxidation of glucose
by the enzyme glucose-oxidase (Glucose +O2 → gluconicacid +H2O2) [30]. The peroxide activity in honey can be
destroyed easily by heat or the presence of catalase in
the body tissues and serum [19]. In vivo use of honey
for human as therapeutic agent, therefore, requires the
evaluation of non-peroxide phytochemical components
of honey. The non-peroxide phytochemical components’
of Manuka Apinae honey (after removing hydrogen perox-
ide by treating with enzyme catalase) from New Zealand
has been found to have substantial levels of antibacterial
activity [31]. Such manuka honey was tested against seven
species of bacteria and was found to have MIC (minimum
inhibitory concentration) that range from 1.8% to 10.8%
(v/v) [32]. This result, therefore, indicated that the major
antimicrobial effect of honey may not be due to hydrogen
peroxide. Propolis (resinous protective barrier) in stingless
bees honey has been reported to have therapeutic effects
against inflammation, heart disease, diabetes mellitus,
microbe’s hepatotoxity, and cancer [27,29]. In agar diffu-
sion, 1% ethanol extracts of propolis were found inhibitory
for growth S. aureus, E. coli, and P. aeruginosa [33]. When
Apis mellifera honey (eucalyptus) and stingless bees honey
were compared, the former had higher phenolic and
flavonoid contents than the stingless bees’ honey, which
in turn had the higher antioxidant activity [34]. The
aim of this study was to evaluate the antibacterial effects
of Ethiopian honeys against antibiotic susceptible and
resistant strains of bacteria so that they would have been
recommended as therapeutic agents after pharmaceutical
standardization and clinical trials.
Methods
Study area and period
Gondar town is located in Amhara region, North West
Ethiopia, at about 723 kms from Addis Ababa. It is located,
at an altitude of around 2, 225 m (above sea level), 12°35′
60.000”N of latitude and 37°28’0.120”E of longitude. White
Apis mellifera honey from Tigray (Northern Ethiopia),
yellow Apis mellifera honey from Gondar (northwest
Ethiopia) and Stingless honey from Gojam (northwest
Ethiopia) were purchased in September and October,
2012 G.C and their antibacterial effects were analyzed
in biotechnology laboratory in University of Gondar
from September 20, 2012 to January 1, 2013 G.C. Only
the stingless bees honey collected from the ground (Tazma
honey) was used for susceptibility test. Attempts were not
made to obtain the stingless bees honey from tree trunks.
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tween the two types of honeys despite the difference in
nesting sites.
Test organisms
Staphylococcus aureus (ATCC 25923), Escherichia coli
(ATCC 25922), Staphylococcus aureus (MRSA), Escherichia
coli (R) and Klebsiella pneumoniae (R) used in this study
were obtained from Gondar University teaching hospital
laboratory.
Preparation of honey solutions
Hundred percent pure honeys (100% v/v) was obtained
after the stingless bees and Apis mellifera honeys were
filtered using sterile gauze. To get 50% honey solutions
(v/v), 1 gm honey was diluted in 1 ml distilled water.
Further serial dilutions were done to obtain 25% and
12.5% honey solutions (v/v).
Preparation of the Mueller Hinton agar (MHA)
Mueller Hinton agar (70191) medium was prepared by
dissolving 38 g of Mueller Hinton agar in 1000 ml dis-
tilled water and boiled until complete dissolutions. The
solution was sterilized in an autoclave (121°C, 1 bar) for
15 min. The suspension was poured (20 ml) into sterile
petri-dishes in the hood to solidify at room temperature.
Preparation of the nutrient broth (7146)
After dissolving 8 g nutrient broth powder in one liter of
purified water, the mixture was mixed thoroughly to
form a clear medium which will be incubated at 35°C
for 18 – 24 hours after the bacterial specimens were
inoculated. Turbidity indicates good growth. Nutrient
broth culture medium can live longer under refrigeration.
Preparation of 0.5 McFarland standards
In this study, 0.5 ml of 0.048 M BaCl2 (1.175%W/V
BaCl2.2H2O) was added to 99.5 mL of 0.18 M H2SO4Table 1 Mean inhibition and standard deviation of stingless b
(ATCC 25923), Staphylococcus aureus (MRSA), Klebsiella pneum
coli (R) at 50% (v/v) concentration
Conc. (v/v) Type of honey N M
50% Stingless honeybees honey 15 16
Apis mellifera white honey 15 17
Apis mellifera yellow honey 15 14
25% Stingless honeybees honey 15 15
Apis mellifera white honey 15 9.0
Apis mellifera yellow honey 15 7.0
12.5% Stingless honeybees honey 15 9.0
Apis mellifera white honey 15 8.0
Apis mellifera yellow honey 15 6.0(1% V/V) with constant stirring to make 0.5 McFarland
Standards [35]. The standard was distributed into a
screw capped test tube of the same size and volume as
those used to prepare the test inoculums. Hundred
micro-liter (100 μl) bacteria sample from nutrient broth
culture media (lot Himedia laboratory, pvt, ltd, India)
was added into 5 ml saline and the concentration was
adjusted to 1–2 ×108 colony forming unit per mill liter
(Cfu/ml) by comparing with McFarland 0.5 standard-
ized [35].Preparation of inoculations and assays of antibacterial
activities
The inoculation of the bacteria was done by streaking
the surface of the plates with sterile swab in a zigzag
manner until the entire surface was covered. With a pre-
viously sterilized cork borer (4 mm) size, wells of equal
distance were bored to drop 100 μl of different anti-
microbial agents (honeys). Hundred micro liters (100 μl)
of 50%, 25% v/v and 12.5% of the honey solutions were
inoculated in to wells of Escherichia coli (ATCC 25922),
Staphylococcus aureus (ATCC 25923), Staphylococcus
aureus (MRSA), Escherichia coli (R) and Klebsiella
pneumoniae (R). The culture plates were incubated at
37°C for 24 h. Inhibition zones were indicated by clear
area around the wells which were measured in millime-
ters by caliper in order to evaluate the degree of suscep-
tibility of the test organisms for 50%, 25% and 12.5
solutions (v/v). This susceptibility test against the differ-
ent honeys solutions were repeated three times to use an
average results.Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC)
Hundred micro-liter (100 μl) bacteria samples from nu-
trient broth culture medium were added into 5 ml saline
and the concentration was adjusted to 1–2 ×108 Cfu/mlees and Apis mellifera honeys on Staphylococcus aureus
oniae (R), Escherichia coli (ATCC 25922) and Escherichia
inimum Maximum Mean Std. deviation
.00 27.00 22.26 3.79
.00 25.00 21.00 2.70
.00 21.00 18.07 2.31
.00 21.00 18.73 1.83
0 18.00 13.67 3.29
0 16.00 10.40 3.58
0 19.00 14.40 2.82
0 17.00 12.40 3.33


















Apis mellifera white honey
Apis mellifera yellow honey
Figure 1 Bacteria inhibitions of 50% solution (v/v) of stingless bees honey, Apis mellifera white and yellow honeys on Staphylococcus
aureus (ATCC 25923), Staphylococcus aureus (MRSA), Klebsiella pneumoniae (R), Escherichia coli (ATCC 25922) and Escherichia coli (R).
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stant stirring before culturing in new broth medium to
determine the lowest concentration of antimicrobial
agent capable of preventing growth (Minimum inhibi-
tory concentrations (MIC)).
The inoculations of Escherichia coli (ATCC 25922),
Staphylococcus aureus (ATCC 25923), Staphylococcus
aureus (MRSA), Escherichia coli (R) and Klebsiella
pneumoniae (R) were done in different nutrient broth
medium containing different concentrations (50%, 25%,
12.5% and 6.25% solutions v/v) of honey solutions. The
tubes were incubated for 20–24 hours at 37°C to observe
turbidity (growth) which indicated the MIC of the differ-
ent honeys on the test organisms.
The minimum bactericidal concentrations (MBCs) were
determined by sub culturing the contents of nutrient
broth used for MIC tests on Mueller Hinton agar media
using sterile wire loop and making a strike on the media
to see bacteria growth after incubating at 37°C for
24 hours. Absence of growth indicated the minimum
bactericidal concentrations (MBCs) of the honeys.Table 2 Results of one way ANOVA from the inhibitions of th
25923), Staphylococcus aureus (MRSA), Klebsiella pneumoniae
showing mean difference for 50% solutions (v/v)
Type of honey Sum of squares
Stingless honey bees honey Between Groups 190.27
Within Groups 10.67
Total 200.93
Apis mellifera white honey Between Groups 78.00
Within Groups 24.00
Total 102.00
Apis mellifera yellow honey Between Groups 62.27
Within Groups 12.67
Total 74.93Drug susceptibility
Drug susceptibility of Staphylococcus aureus (ATCC
25923), Staphylococcus aureus (MRSA), Klebsiella
pneumoniae (R), Escherichia coli (ATCC 25922) and
Escherichia coli (R) cultures were determined using
at least three of the following antibiotics discs: Tetracyc-
line, vancomycin, amoxicillin, methicillin, Erythromycin
and penicillin. The result was interpreted as resistant,
intermediate or susceptible by comparing the results with
what has already been reported by Clinical and Laboratory
Standards Institute (CLSI) [36].
Statistical analysis
The antibacterial effects (inhibitions) of honeys (mean ± SD)
were compared using descriptive statistics. All statistical
analysis has been performed by using statistical package
of social science (SPSS) version 20. Comparison of honey
extracts, for their mean inhibitions, were analyzed using
one way analysis of variance (ANOVA). Mean inhibitions
of the different honey solutions were considered signifi-
cantly different for P value less than 0.05.e three types of honeys on Staphylococcus aureus (ATCC
(R), Escherichia coli (ATCC 25922) and Escherichia coli (R)
Degrees of freedom (df) Mean square F Sig.
4 47.57 44.59 .000
10 1.07
14
4 19.50 8.13 .003
10 2.40
14
4 15.57 12.29 .001
10 1.27
14
Table 3 Minimum inhibitory concentration (MIC) values of
stingless honey, Apis mellifera white honey and Apis
mellifera yellow honey against drug susceptible
(Staphylococcus aureus (ATCC 25923) and Escherichia coli
(ATCC 25922)) and resistant clinical isolate (Staphylococcus
aureus (MRSA), Klebsiella pneumoniae (R), and Escherichia
coli (R)) at 50% (v/v) concentration










E.coli(S) 6.25 6.25 6.25
S. aureu(S) 6.25 6.25 6.25
E.coli(R) 6.25 12.25 12.25
K. pn (R) 6.25 12.25 12.25
S. au(R) 12.25 12.25 12.25
% at 6.25 80% 40% 40%
% at 12.5 20% 60% 60%
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The overall mean inhibitions of the 50% honey concen-
trations (v/v) were higher compared with 25% and
12.5% concentrations on Staphylococcus aureus (ATCC
25923), Staphylococcus aureus (MRSA), Escherichea coli
(ATCC 25922), Escherichia coli (R) and Klebsiella
pneumoniae (R) (Table 1). The highest inhibition
(27 mm) was produced by stingless bees honey on both
susceptible E. coli (ATCC25922) and S. aureus
(ATCC25923). Of all the three types of honeys, the
stingless bees honey produced the leading inhibitions
on almost all the standard and resistant test organisms.
Apis mellifera yellow honey produced the least effect
(Figure 1). A one-way between-groups analysis of variance
using Post-hoc comparisons using the Tukey tests have
shown statistically significant mean differences at
the p < 0.05 level for inhibitions of stingless honeyTable 4 Antibacterial effect (susceptible, intermediate and re
Erythromycin, Methicillin (5 μg), Ampicillin (10 μg), Amoxicill
antibiotic discs on drug susceptible (Escherichia coli (ATCC 25
clinical isolate (Staphylococcus aureus (MRSA), Escherichia coli




Amoxicillin (25 μg) S R
Ampicillin (10 μg) _ _
Methicillin (5 μg) I R
Kanamycin (30 μg) S _
Penicillin (10 μg) R R
Tetracycline (30 μg) S _
Erythromycine _ _
vancomycin (30 μg) S _
Keys: - S = susceptible; I = intermediate; R = resistant.bees honey (Mean ± SD = 22.27 ± 3.78, df = 14, F = 44.59,
P <0.05), white honey ( 21 ± 2.69, df = 14, F= 8.13, P < 0.05)
and yellow honey ( 18 ± 2.31, df = 14, F =12.29, P < 0.05 ) on
Staphylococcus aureus (ATCC 25923), Staphylococcus
aureus (MRSA), Escherichea coli (ATCC 25922),
Escherichea coli (R) and Klebsiella peumoniae (R) at
50% concentration (v/v) (Table 2). Similarly, statistically
significant mean differences were observed for 25% and
12.5% concentrations (v/v). Stingless bees Tazma honey
have 6.25% (6.25 mg/ml) MIC value for 80% of the test
organisms compared to 40% for Apis mellifera white
and yellow honeys (Table 3). All the honeys were found
to have 12.5% (12.5 mg/ml) Minimum Bactericidal
Concentration (MBC).
Tetracycline, Amoxicillin and Kanamycin standard anti-
biotic discs produced 22 mm, 25 mm and 20 mm inhib-
ition zones on susceptible Staphylococcus aureus (ATCC
25923) respectively. Susceptible Escherichia coli (ATCC
25922) also inhibited by tetracycline (21 mm), kanamycin
(20 mm) and erythromycin (10 mm) standard antibiotic
discs. Tetracycline and methicillin antibiotic discs did
not produce inhibition on Staphylococcus aureus (MRSA)
while amoxicillin produced very low (10 mm) inhibition.
Methicillin disc produced no inhibition on resistant
E. coli. Similarly, Ampicillin, erythromycin and methicillin
did not produce inhibitions on resistant Klebsiella
pneumoniae (R) strain (Table 4).
Discussion
The inhibitions of Apis mellifera white Tigray honey
(25 mm for Staphylococcus aureus (ATCC 25923) and
22 mm for Escherichia coli (ATCC 25922)) and stingless
bees Gojam Tazma honey (27 mm for Staphylococcus
aureus (ATCC 25923); 26 mm for Escherichia coli (ATCC
25922)) at concentration of 50% solution (w/v) were as
effective as inhibitions of standard tetracycline discs already
reported (83). In this study, the inhibitions produced bysistant) of Tetracycline (30 μg), Kanamycine (30 μg),
ine (25 μg), Penicillin (10 μg) and Vancomycine (30 μg)
922) & Staphylococcus aureus (ATCC 25923) and resistant
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honey on Staphylococcus aureus (ATCC 25923) and
Escherichia coli (ATCC 25922) at 50% concentration
(v/v) (Figure 1) was greater than inhibitions produced
by amoxicillin (25 μg), Methicillin (5 μg), Kanamycin
(30 μg), Penicillin (10 μg) and Tetracycline (30 μg) discs
(Table 4). Unlike the honeys, Methicillin, erythromycin,
ampicillin and amoxicillin discs did not produce signifi-
cant antibacterial effects on the resistant strains of bacteria
(Table 4). These results have indicated the potential of
honeys as therapeutic agents to treat both susceptible
and drug resistant bacteria. The inhibitions of the 25%
concentration of stingless honeybees honey (Tazma)
solutions (v/v) in this study were similar to previous
study [10]. Antibacterial effects of honey solutions
decreased up on serial dilution from 50% to 25% which
has also been reported elsewhere [19].
Of the three types of honeys analyzed, stingless bees
tazma honeys were found to have the highest antimicrobial
activities against susceptible bacteria compared to Apis
mellifera white Tigray honey (Table 1). The presence of
bactericidal resins (propolis) might have given extra
antimicrobial effect of stingless bees Gojam tazma honey
as already reported [37]. The difference between Apis
mellifera white and yellow honeys could be related to
floral sources of honeys as already reported in another
study [6]. Apis mellifera in Tigray often make their honey
from white flower of Cactus plant (Opuntia spp) unlike
Gondar region where Apis mellifera use different plants as
source of honey. The difference in floral sources, in these
two localities, might explain the difference in antibacterial
effects of Apis mellifera Tigray white and Gondar yellow
honeys.
MIC of White and yellow honeys for 40% of the test
organisms was 6.25% (Table 3). But, Mulu et al., (2004)
[8] reported MIC values to be 6.25% for 90% of the test
organisms. This difference could be related to difference
in contents of the honeys as the two researches were
conducted in different parts of Ethiopia in addition to
the difference in tested organisms. The MIC value for
stingless bees Tazma honey was 6.25% (6.25 mg/ml) for
80% of test organisms which was slightly higher than
previous report [10]. The difference could be related to
difference in the floral contents used to prepare the
honeys. The minimum bactericidal concentration for this
study was 12.5% (12.5 mg/ml) for all the test organisms
compared to 6.25% for 70% the test organisms in another
study [8] which might have been related to the floral
contents used to prepare the honeys.
The results of antibiotic tests in this study on the
susceptible standard Escherichia coli (ATCC 25922) and
Staphylococcus aureus (ATCC 25923) were within the ac-
ceptable range (Table 1). But, the resistant clinical iso-
lates (Staphylococcus aureus (MRSA), Escherichia coli (R)and Klebsiella pneumoniae (R)) were not effectively
inhibited by methicillin, erythromycin, ampicillin and
amoxicillin discs indicating the wide spread of drug re-
sistant strains in the Gondar teaching referral hospital.
Similar wide spread of β-lactamase producing drug resist-
ant bacteria strains were reported to exist in the Hospitals
(6–8). The results of this study has shown the potential
of Apis mellifera white Tigray honey and stingless bees
Gojam Tazma honey to be used to treat β-lactamase
producing drug resistant bacteria strains in Ethiopia.
Further clinical trial and pharmaceutical standardization
of honeys are recommended before any use of the honeys
as therapeutic agents.
Conclusion
In conclusion, all the three types of honeys were not the
same in their antibacterial effects. The leading bacterial
inhibitions were produced by stingless bees honey and
followed by Apis Mellifera white honey. The fact that in-
hibitions of these honeys were superior, over the most
common antibiotics used to treat bacteria, makes them a
novel source of chemotherapeutic agents to treat drug
resistant bacteria in future.
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